Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene
Open Access
- 1 January 2003
- journal article
- research article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 3 (3) , 169-177
- https://doi.org/10.1038/sj.tpj.6500170
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Polymorphisms of Arylamine N-Acetyltransferase (NAT1 and NAT2) and Larynx Cancer SusceptibilityORL, 2002
- Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancerCarcinogenesis: Integrative Cancer Research, 2002
- The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differencesToxicology Letters, 2002
- Arylamine N-acetyltransferases – of mice, men and microorganismsTrends in Pharmacological Sciences, 2001
- Placental arylamine N-acetyltransferase type 1: potential contributory source of urinary folate catabolite p-acetamidobenzoylglutamate during pregnancyBiochimica et Biophysica Acta (BBA) - General Subjects, 2000
- Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryosHuman Molecular Genetics, 2000
- Localization of N-Acetyltransferases NAT1 and NAT2 in Human TissuesToxicological Sciences, 2000
- Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cellsBiochemical Journal, 1995
- Acetyltransferase in Humans: Development and Tissue DistributionPharmacology, 1986
- Genetic Control of Isoniazid Metabolism in ManBMJ, 1960